• 한국정보과학회논문지:데이타베이스
• /
• 제31권3호
• /
• pp.205-218
• /
• 2004

시공간 데이타관리를 위한 데이타베이스 기술이 발전함에 따라 방대한 시공간 데이타 집합으로부터 의미 있는 시공간 지식 탐사를 필요로 하는 시공간 응용 서비스가 증대되고 있다. 이 논문에서는 시공간 지식 탐사 기법 개발을 지원하기 위하여 시공간 3계층 지식탐사 프레임워크를 제안하였다. 프레임 워크에서는 시공간 지식 탐사 문제 정의를 위한 기반 모델을 제시하여 시공간 지식에 대한 정의 및 관계를 표현할 수 있도록 하였다. 또한 시공간 지식 탐사 시스템의 구성요소 및 구현 모델을 제시하였다. 이 논문에서 제안한 시공간 지식 탐사를 위한 프레임워크는 앞으로 새로운 유형의 시공간 지식 탐사 기법 개발에 적용될 수 있는 특징을 포함하고 있다. 제안한 프레임워크는 시공간 이동 패턴과 같은 새로운 유형의 지식 탐사 기법 개발 지원에 있어 시공간 데이타 집합, 정보 및 지식에 대한 관계 규정과 각 요소에 대한 표현 모델을 제공함으로써 지식 탐사 문제를 형식화하고 단순화할 수 있다.

• Biomolecules & Therapeutics
• /
• 제21권6호
• /
• pp.411-422
• /
• 2013

G-protein-coupled receptors (GPCR) are the largest superfamily of receptors responsible for signaling between cells and tissues, and because they play important physiological roles in homeostasis, they are major drug targets. New technologies have been developed for the identification of new ligands, new GPCR functions, and for drug discovery purposes. In particular, intercellular lipid mediators, such as, lysophosphatidic acid and sphingosine 1-phosphate have attracted much attention for drug discovery and this has resulted in the development of fingolimod (FTY-720) and AM095. The discovery of new intercellular lipid mediators and their GPCRs are discussed from the perspective of drug development. Lipid GPCRs for lysophospholipids, including lysophosphatidylserine, lysophosphatidylinositol, lysophosphatidylcholine, free fatty acids, fatty acid derivatives, and other lipid mediators are reviewed.

• KDI Journal of Economic Policy
• /
• 제41권4호
• /
• pp.45-66
• /
• 2019

This paper empirically examines what role of existing exporters play in the discovery of new export products and whether there are evidence of spillovers from export discovery. We find that existing exporters are more likely to discover new export products than non-exporters. We also find evidence of export discovery spillovers; export discovery of a product by some plants had an effect of increasing the probability of subsequent export market penetration of the same product by other plants. Export discovery spillovers are found to be stronger among geographically closely located plants. We argue that information spillovers is a part of the story: you learn from your neighboring discoverers about the profitability of potentially exportable products.

• 한국컴퓨터정보학회논문지
• /
• 제25권10호
• /
• pp.51-58
• /
• 2020

DDS 디스커버리는 같은 도메인을 사용하고, 다른 노드에 존재하는 DDS 객체를 찾는 과정이다. 한 노드에서 DDS 디스커버리 과정이 실패한다면, DDS 디스커버리가 실패한 노드에서 정상적인 DDS 데이터 송수신이 불가능하여 시스템 운용에 큰 영향을 미칠 수 있다. 그렇기 때문에, DDS 디스커버리의 성능을 향상시켜 DDS 디스커버리 과정을 빠르게 완료하고, 네트워크 부하와 컴퓨터 자원 사용량을 줄여서 DDS 디스커버리가 실패할 수 있는 가능성을 줄일 수 있다면 전체 시스템의 성능 향상에 큰 영향을 줄 수 있다. 본 논문에서는 대용량 시스템에서 DDS 디스커버리 시간과 네트워크 부하, 컴퓨터 자원 사용량을 줄일 수 있는 성능 향상을 위한 새로운 방법을 제안하고, 시험을 통하여 제안한 방법의 효율성을 증명한다.

• Natural Product Sciences
• /
• 제19권2호
• /
• pp.150-154
• /
• 2013

A new oleanane-type triterpenoid saponin together with six known saponins were isolated from the roots of Pulsatilla cernua. Their structures were elucidated on the basis of spectroscopic data, including 2D NMR spectra and chemical evidence. Compounds 1 and 6 are reported from this genus for the first time.

• Biomolecules & Therapeutics
• /
• 제22권5호
• /
• pp.400-405
• /
• 2014

G-protein coupled receptor 119 (GPR119) has emerged as a novel target for the treatment of type 2 diabetes mellitus. GPR119 is involved in glucose-stimulated insulin secretion (GSIS) from the pancreatic b-cells and intestinal cells. In this study, we identified a novel small-molecule GPR119 agonist, HD047703, which raises intracellular cAMP concentrations in pancreatic ${\beta}$-cells and can be expected to potentiate glucose-stimulated insulin secretion from human GPR119 receptor stably expressing cells (CHO cells). We evaluated the acute efficacy of HD047703 by the oral glucose tolerance test (OGTT) in normal C57BL/6J mice. Then, chronic administrations of HD047703 were performed to determine its efficacy in various diabetic rodent models. Single administration of HD047703 caused improved glycemic control during OGTT in a dose-dependent manner in normal mice, and the plasma GLP-1 level was also increased. With respect to chronic efficacy, we observed a decline in blood glucose levels in db/db, ob/ob and DIO mice. These results suggest that HD047703 may be a potentially promising anti-diabetic agent.

• 대한약학회:학술대회논문집
• /
• 대한약학회 2001년도 Proceedings of the Pharmaceutical Society of Korea
• /
• pp.241.2-241.2
• /
• 2001

• 한국정보과학회:학술대회논문집
• /
• 한국정보과학회 2007년도 가을 학술발표논문집 Vol.34 No.2 (B)
• /
• pp.17-21
• /
• 2007

Drug discovery is a long process with a low rate of successful new therapeutic discovery regardless of the advances in information technologies. Identification of candidate proteins is an essential step for the drug discovery and it usually requires considerable time and efforts in the drug discovery. The drug discovery is not a logical, but a fortuitous process. Nevertheless, considerable amount of information on drugs are accumulated in UniProt, NCBI, or DrugBank. As a result, it has become possible to try to devise new computational methods classifying drug target candidates extracting the common features of known drug target proteins. In this paper, we devise a method for drug target protein classification by using weighted feature summation and Support Vector Machine. According to our evaluation, the method is revealed to show moderate accuracy $85{\sim}90%$. This indicates that if the devised method is used appropriately, it can contribute in reducing the time and cost of the drug discovery process, particularly in identifying new drug target proteins.

• Biomolecules & Therapeutics
• /
• 제22권4호
• /
• pp.267-274
• /
• 2014

Drug development and preclinical trials are challenging processes and more than 80% to 90% of drug candidates fail to gain approval from the United States Food and Drug Administration. Predictive and efficient tools are required to discover high quality targets and increase the probability of success in the process of new drug development. One such solution to the challenges faced in the development of new drugs and combination therapies is the use of low-cost and experimentally manageable in vivo animal models. Since the 1980's, scientists have been able to genetically modify the mouse genome by removing or replacing a specific gene, which has improved the identification and validation of target genes of interest. Now genetically engineered mouse models (GEMMs) are widely used and have proved to be a powerful tool in drug discovery processes. This review particularly covers recent fascinating technologies for drug discovery and preclinical trials, targeted transgenesis and RNAi mouse, including application and combination of inducible system. Improvements in technologies and the development of new GEMMs are expected to guide future applications of these models to drug discovery and preclinical trials.

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 1994년도 제2회 추계심포지움
• /
• pp.93-98
• /
• 1994

Most drug discovery has focused in recent years on the development of molecules that either interact with or block receptors, proteins that act as on-off switches for genetic activity, on the surfaces of human cells. Now, we have developed a technology that targets “receptors inside the cell” (intracellular receptors), opening a new and compelling avenue for drug discovery. Our receptor-based small molecule drugs can be catagorized in two ways: 1) receptor agonists, or molecules that activate a receptor; and 2) receptor antagonists, or drugs that inactivate a receptor.